Epcoritamab Plus R-CHOP Cuts Lymphoma Progression Risk in Trial
Genmab and AbbVie report epcoritamab combined with R-CHOP met its primary endpoint in newly diagnosed DLBCL patients.
Genmab and AbbVie announced that epcoritamab, a bispecific antibody, demonstrated a statistically significant improvement in progression-free survival when combined with the standard chemotherapy regimen R-CHOP in patients newly diagnosed with diffuse large B-cell lymphoma, the most common form of aggressive non-Hodgkin lymphoma.
The results, drawn from a clinical trial, indicate the combination regimen cleared the study's primary endpoint, a milestone that could position epcoritamab as a potential new front-line treatment option for a disease that remains difficult to treat despite decades of research into chemotherapy-based approaches.
Read more Forum Markets, Edge Node AI Partner to Deploy Inference Compute Across US →
Diffuse large B-cell lymphoma, or DLBCL, accounts for roughly 30 percent of all non-Hodgkin lymphoma diagnoses in the United States. While R-CHOP has been the standard of care for newly diagnosed patients for more than two decades, a substantial share of patients relapse or fail to respond, underscoring the clinical need for regimens that can improve upon that benchmark.
Epcoritamab is a CD3xCD20 bispecific antibody designed to direct a patient's own T-cells to attack cancerous B-cells. The drug was previously approved for relapsed or refractory DLBCL, making this trial a significant step toward establishing its role earlier in the treatment pathway. The collaboration between Danish biotech Genmab and pharmaceutical giant AbbVie has been central to advancing the compound through clinical development.
Continue reading at GlobeNewswire - Industry News on Financial Services.
